AI For Pharma Growth

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr Eugene Chan of Behavieural about why many AI failures in pharma are not really technical failures at all. 
They are human problems involving trust, judgement, behaviour and adoption.
Eugene explains that even when the technology works, people may ignore it, override it or over-trust it. Clinicians, scientists and executives bring their own biases, habits, incentives and sense of professional identity to every AI-assisted decision.
The conversation explores why autonomy matters, how cognitive load changes behaviour, and why one incorrect AI output can damage trust far beyond that single mistake. Eugene also discusses automation bias, the risks of simply clicking approve, and why explainability needs to help judgement rather than replace it.
They also look at change management and why one-off training is not enough. If organisations want AI adoption to stick, behavioural interventions need to become part of workflow design, governance and organisational culture.
The key message is that having the best model, policy or governance framework is not enough if it assumes people will behave rationally.
Behavieural - https://behavieural.com/ 
Topics Covered
Why pharma AI adoption is a behavioural problem

Trusting and distrusting AI

Automation bias and over-reliance

Professional identity and autonomy

Cognitive load and decision making

Why one bad output can damage long-term trust

Human judgement versus AI recommendations

Change management and behaviour change

Designing governance around real human behaviour

About Eularis
Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.
Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.
The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.
AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.
AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.
Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.com

About the Podcast
AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.

Dr. Andree Bates LinkedIn | Facebook | X

In this solo episode of AI For Pharma Growth, Dr Andree Bates explores what health technology assessment bodies now expect when AI is used to generate, analyse or support evidence.
The episode looks at the emerging principles from NICE in England, CDA-AMC in Canada and the EU Joint Clinical Assessment framework. While none of these bodies has banned AI, Andree explains that organisations are increasingly expected to be able to justify where AI was used, how it was used, who was responsible for checking it and whether the process can be reconstructed.
She breaks the expectations into four core areas: accountability, human oversight, transparency and reporting. That includes recording tools, versions, dates, prompts, adaptations and the specific role AI played in screening, extraction, analysis or reporting.
Andree also highlights one of the biggest practical risks: automation bias. Human oversight cannot simply mean somebody glanced at the output. It means having a named person who can explain what was checked, how it was checked and why the level of verification was appropriate for that task.
The key message is that AI can still accelerate evidence generation, but teams now need the documentation and governance to defend its use.
Topics Covered
NICE, CDA-AMC and EU JCA expectations

Accountability for AI-assisted evidence

Human oversight and automation bias

Declaring AI tools and methods

Recording prompts, versions and outputs

Screening versus extraction risk

Copyright, data protection and security

AI use across vendors and CROs

Building an audit trail before submission

What assessors may ask next

About Eularis
Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.
Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.
The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.
AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.
AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.
Start with the Institute → https://eularis.com/institute/
Everything else → https://eularis.com

About the Podcast
AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.

Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Mattia Marco Caruson, co-founder and CEO of mama health, about how generative AI is changing the way pharma understands the patient journey.
Mattia explains why traditional methods such as surveys, focus groups and clinician interviews often capture only fragments of what patients actually experience. In rare and chronic diseases, the most important parts of the journey can happen between appointments, long before a patient reaches the right doctor or treatment.
The conversation explores how generative AI can enable open-ended conversations with patients at scale and then turn those qualitative stories into structured, analysable data. Instead of forcing people to reduce years of lived experience to a multiple-choice answer, AI can help capture their own words, frustrations, unmet needs and decision points.
Mattia also discusses how these insights can influence launch strategy, positioning, patient support, medical affairs and market access. He argues that pharma should stop viewing AI only as a way to make existing processes faster and start asking what entirely new capabilities it unlocks.
They also examine consent, privacy, hallucination risk and the need to ground patient-facing AI in trusted medical sources.
Topics Covered
Why surveys miss important parts of the patient journey

AI-powered patient conversations at scale

Turning qualitative stories into structured insight

Understanding unmet needs and treatment decisions

Patient insight for launch and commercial strategy

Consent, privacy and data governance

Grounding AI in trusted medical knowledge

Why pharma needs to listen directly to patients

About Eularis
Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.
Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.
The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.
AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.
AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.
Start with the Institute → https://eularis.com/institute/
Everything else → https://eularis.com
About the Podcast
AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.

Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Kurt Rohloff, co-founder and CEO of Duality Technologies, about how privacy-enhancing technologies could unlock data collaboration without forcing organisations to give up control of sensitive information.
Kurt explains how technologies such as fully homomorphic encryption and federated learning allow organisations to analyse encrypted or distributed data without exposing the underlying patient information. For pharma and medical research, that creates opportunities to reuse existing data, collaborate across organisations and geographies, and access populations that have historically been difficult to include.
The conversation explores why data security should not be viewed only as a compliance cost. Secure collaboration can also become a value creator, helping organisations run better science, reduce administrative overhead and generate evidence that would otherwise be too expensive or difficult to obtain.
They also discuss rare diseases, underserved communities, cross-border research and the role regulators and standards bodies will play in enabling wider adoption. Kurt argues that the technology is often further ahead than organisational acceptance, making policy conversations just as important as technical development.
Topics Covered
Privacy-enhancing technologies in pharma

Fully homomorphic encryption

Federated learning and secure analytics

Reusing clinical and research data

Cross-border collaboration

Rare diseases and underserved populations

Data sovereignty and regulatory acceptance

Secure AI and LLM workloads

About Eularis
Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.
Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.
The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.
AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.
AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.
Start with the Institute → https://eularis.com/institute/
Everything else → https://eularis.com
About the Podcast
AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.

Dr. Andree Bates LinkedIn | Facebook | X

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Clara Bernardes, co-founder and CSO of Biorce, about how AI can accelerate clinical development without sacrificing compliance or scientific rigour.
Biorce was born from a deeply personal experience. After Clara's father-in-law received a terminal melanoma diagnosis, access to a clinical trial through compassionate use extended his life from an expected three months to more than a year. That experience shaped Biorce's mission: reduce the time it takes promising treatments to reach patients.
Clara explains why clinical trials are still slowed by protocol amendments, patient identification problems, poorly designed criteria and human-led errors that could often be caught much earlier.
The conversation explores how Biorce uses AI and almost one million annotated protocols to support protocol development, learn from previous trial amendments and provide clear rationale for recommendations. Clara also discusses why transparency, AI ethics and keeping humans in the loop are essential in regulated clinical development.
The key message is that speed and compliance do not have to be opposing forces. The goal is not to replace scientists or investigators, but to give them better information faster while preserving human judgement.
Topics Covered
Why clinical trials start late

Protocol amendments and avoidable human error

AI-generated clinical trial protocols

Learning from previous trial failures

Transparency and explainability

AI ethics and regulatory compliance

Keeping humans in the loop

Balancing quality with velocity

What sponsors should ask AI vendors

About Eularis
Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies.
Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work.
The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges.
AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny.
AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint.
Start with the Institute → https://eularis.com/institute/
Everything else → https://eularis.com
About the Podcast
AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma.

Dr. Andree Bates LinkedIn | Facebook | X